Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

Documents similaires

• CTLA-4 blockade in the treatment of colorectal cancer with microsatellite instability
  par: Diana Russo, et autres
  Publié: (2021)
• Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
  par: Lewis Zhichang Shi, et autres
  Publié: (2016)
• Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity.
  par: W Joost Lesterhuis, et autres
  Publié: (2013)
• Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
  par: Clélia Coutzac, et autres
  Publié: (2020)
• MINOR SUBSETS OF T-HELPER CELLS (Th THYMIC NAIVE, Th CENTRAL NAIVE, Th9, Th22 AND CD4+CD8+ DOUBLE POSITIVE T-CELLS)
  par: S. V. Khaidukov
  Publié: (2014)